Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy.

Nebozhyn M, Loboda A, Kari L, Rook AH, Vonderheid EC, Lessin S, Berger C, Edelson R, Nichols C, Yousef M, Gudipati L, Shang M, Showe MK, Showe LC.

Blood. 2006 Apr 15;107(8):3189-96. Epub 2006 Jan 10.

2.

CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214.

Benoit BM, Jariwala N, O'Connor G, Oetjen LK, Whelan TM, Werth A, Troxel AB, Sicard H, Zhu L, Miller C, Takeshita J, McVicar DW, Kim BS, Rook AH, Wysocka M.

Arch Dermatol Res. 2017 Jan;309(1):11-19. doi: 10.1007/s00403-016-1698-8. Epub 2016 Oct 20.

PMID:
27766406
3.

Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.

Klemke CD, Fritzsching B, Franz B, Kleinmann EV, Oberle N, Poenitz N, Sykora J, Banham AH, Roncador G, Kuhn A, Goerdt S, Krammer PH, Suri-Payer E.

Leukemia. 2006 Jun;20(6):1123-9.

PMID:
16557241
4.

CD158K/KIR3DL2 transcript detection in lesional skin of patients with erythroderma is a tool for the diagnosis of Sézary syndrome.

Ortonne N, Le Gouvello S, Mansour H, Poillet C, Martin N, Delfau-Larue MH, Leroy K, Farcet JP, Bagot M, Bensussan A.

J Invest Dermatol. 2008 Feb;128(2):465-72. Epub 2007 Aug 16.

5.

Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.

Poenitz N, Simon-Ackermann J, Gratchev A, Qadoumi M, Klemke CD, Stadler R, Kremer A, Radenhausen M, Henke U, Assaf C, Utikal J, Goerdt S, Dippel E.

Dermatology. 2005;211(2):84-92.

PMID:
16088151
6.

Sézary syndrome without erythroderma: A review of 16 cases at Mayo Clinic.

Thompson AK, Killian JM, Weaver AL, Pittelkow MR, Davis MD.

J Am Acad Dermatol. 2017 Apr;76(4):683-688. doi: 10.1016/j.jaad.2016.10.029. Epub 2016 Dec 21.

PMID:
28012574
8.

Utility of flow cytometry immunophenotyping and DNA ploidy studies for diagnosis and characterization of blood involvement in CD4+ Sézary's syndrome.

Lima M, Almeida J, dos Anjos Teixeira M, Queiros ML, Santos AH, Fonseca S, Balanzategui A, Justica B, Orfao A.

Haematologica. 2003 Aug;88(8):874-87.

9.

Histopathologic diagnosis of lymphomatous versus inflammatory erythroderma: a morphologic and phenotypic study on 47 skin biopsies.

Ram-Wolff C, Martin-Garcia N, Bensussan A, Bagot M, Ortonne N.

Am J Dermatopathol. 2010 Dec;32(8):755-63. doi: 10.1097/DAD.0b013e3181cfbfbf.

10.

Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma.

Scarisbrick JJ, Whittaker S, Evans AV, Fraser-Andrews EA, Child FJ, Dean A, Russell-Jones R.

Blood. 2001 Feb 1;97(3):624-30.

11.

Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.

Fraser-Andrews EA, Mitchell T, Ferreira S, Seed PT, Russell-Jones R, Calonje E, Whittaker SJ.

Br J Dermatol. 2006 Oct;155(4):756-62.

PMID:
16965425
12.

Detection of clonal T-cell receptor gamma gene rearrangements in early mycosis fungoides/Sezary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE).

Wood GS, Tung RM, Haeffner AC, Crooks CF, Liao S, Orozco R, Veelken H, Kadin ME, Koh H, Heald P, et al.

J Invest Dermatol. 1994 Jul;103(1):34-41.

13.

Diagnostic value of dominant T-cell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma.

Delfau-Larue MH, Laroche L, Wechsler J, Lepage E, Lahet C, Asso-Bonnet M, Bagot M, Farcet JP.

Blood. 2000 Nov 1;96(9):2987-92.

14.

Differential expression of TOX by skin-infiltrating T cells in Sézary syndrome and erythrodermic dermatitis.

Boonk SE, Çetinözman F, Vermeer MH, Jansen PM, Willemze R.

J Cutan Pathol. 2015 Sep;42(9):604-9. doi: 10.1111/cup.12490. Epub 2015 May 6.

PMID:
25777533
15.
16.

Sarcoidal tissue reaction in Sézary syndrome.

Gregg PJ, Kantor GR, Telang GH, Lessin SR, Nowell PC, Vonderheid EC.

J Am Acad Dermatol. 2000 Aug;43(2 Pt 2):372-6. Review.

PMID:
10901727
17.

A case of erythrodermic-CTCL.

Shimoda T, Aoki M, Takezaki S, Futagami A, Inokuchi K, Sugisaki Y, Kawana S.

Leuk Lymphoma. 2006 Aug;47(8):1708-10. No abstract available.

PMID:
16966295
18.

Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3.

Booken N, Gratchev A, Utikal J, Weiss C, Yu X, Qadoumi M, Schmuth M, Sepp N, Nashan D, Rass K, Tüting T, Assaf C, Dippel E, Stadler R, Klemke CD, Goerdt S.

Leukemia. 2008 Feb;22(2):393-9. Epub 2007 Nov 22.

PMID:
18033314
19.

EPHA4 is overexpressed but not functionally active in Sézary syndrome.

Hameetman L, van der Fits L, Zoutman WH, Out-Luiting JJ, Siegal G, de Esch IJ, Vermeer MH, Tensen CP.

Oncotarget. 2015 Oct 13;6(31):31868-76. doi: 10.18632/oncotarget.5573.

20.

Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma.

Hahtola S, Tuomela S, Elo L, Häkkinen T, Karenko L, Nedoszytko B, Heikkilä H, Saarialho-Kere U, Roszkiewicz J, Aittokallio T, Lahesmaa R, Ranki A.

Clin Cancer Res. 2006 Aug 15;12(16):4812-21.

Supplemental Content

Support Center